Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MNKD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic P… NCT07679893 · Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosi… Nintedanib Dry Powder Inhalation, Placebo | MNKD Mannkind Corporation | Phase 2 | Recruiting | 153 | Dec 30, 2027 | Registry ↗ |
| Aug 13, 2026 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes NCT07224321 · Type 1 Diabetes Mellitus Technosphere Insulin, Technosphere Insulin | MNKD Mannkind Corporation | Phase 2 | Recruiting | 100 | Mar 2027 | Registry ↗ |
| Jul 22, 2026 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopath… NCT07344558 · Idiopathic Pulmonary Fibrosis (IPF) MNKD-201(Nintedanib DPI), Placebo | MNKD Mannkind Corporation | Phase 1 | Completed | 27 | Jun 17, 2026 | Registry ↗ |
| Nov 12, 2025 | ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation… NCT06418711 · MAC Lung Disease, Treatment Refractory MAC Lung Disease Clofazimine Inhalation Suspension, Placebo | MNKD Mannkind Corporation | Phase 3 | Terminated | 132 | Nov 10, 2025 | Registry ↗ |
| May 6, 2025 | Afrezza® INHALE-1 Study in Pediatrics NCT04974528 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 Afrezza, Rapid-acting Insulin Analog | MNKD Mannkind Corporation | Phase 3 | Completed | 319 | Oct 3, 2024 | Registry ↗ |
| Apr 8, 2025 | Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults… NCT05243628 · Type 1 Diabetes Afrezza (insulin human) Inhalation Powder, insulin degludec | MNKD Mannkind Corporation | Phase 4 | Completed | 33 | Oct 17, 2022 | Registry ↗ |
| Aug 9, 2024 | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes NCT05904743 · Diabetes Mellitus, Type 1 Afrezza, insulin degludec | MNKD Mannkind Corporation | Phase 4 | Completed | 141 | Mar 26, 2024 | Registry ↗ |
| Aug 6, 2024 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers NCT06532942 · Healthy Volunteers (Part A) MKND-201, Placebo | MNKD Mannkind Corporation | Phase 1 | Unknown | 40 | Oct 31, 2024 | Registry ↗ |
| Sep 18, 2023 | Afrezza® Dosing Optimization Study NCT04849845 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 Afrezza Dose 1, Afrezza Dose 2 | MNKD Mannkind Corporation | Phase 4 | Completed | 20 | May 28, 2021 | Registry ↗ |
| Apr 6, 2021 | Afrezza Safety and Pharmacokinetics Study in Pediatric Patients NCT02527265 · Type 1 Diabetes Mellitus Afrezza | MNKD Mannkind Corporation | Phase 2 | Completed | 30 | Mar 17, 2020 | Registry ↗ |
| Oct 30, 2018 | Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volun… NCT03464864 · Pulmonary Arterial Hypertension Treprostinil Inhalation Powder | MNKD Mannkind Corporation | Phase 1 | Completed | 36 | Jun 5, 2018 | Registry ↗ |
| Apr 14, 2017 | Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmon… NCT00642616 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus Technosphere® Insulin, Usual Care | MNKD Mannkind Corporation | Phase 3 | Terminated | 34 | Nov 2014 | Registry ↗ |
| Apr 13, 2017 | Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Lev… NCT02470637 · Type 1 Diabetes Mellitus SAR439065, Insulin lispro | MNKD Mannkind Corporation | Phase 1 | Completed | 30 | Sep 2015 | Registry ↗ |
| Mar 15, 2017 | PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Pa… NCT02485327 · Type 1 Diabetes Mellitus Technosphere Insulin SAR439065 Afrezza® | MNKD Mannkind Corporation | Phase 1 | Completed | 22 | Nov 2015 | Registry ↗ |
| Jan 20, 2016 | Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder NCT01798914 · Type 1 Diabetes, Type 2 Diabetes Technosphere Insulin Inhalation Powder | MNKD Mannkind Corporation | — | No longer available | — | Apr 2015 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances